This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
This two-day program was attended by 40 doctors & paramedical staff
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
India Business grew by 11.9% YoY to Rs. 1196.2 crore
The partnership marks a significant milestone in integrating digital health education into medical curricula
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pradaxa Capsules, 110 mg of Boehringer Ingelheim Pharmaceuticals
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Subscribe To Our Newsletter & Stay Updated
